Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Literature DB >> 30510087

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab.

Richard W Joseph, Jeroen Elassaiss-Schaap, Richard Kefford, Wen-Jen Hwu, Jedd D Wolchok, Anthony M Joshua, Antoni Ribas, F Stephen Hodi, Omid Hamid, Caroline Robert, Adil Daud, Roxana Dronca, Peter Hersey, Jeffrey S Weber, Amita Patnaik, Dinesh P de Alwis, Andrea Perrone, Jin Zhang, S Peter Kang, Scot Ebbinghaus, Keaven M Anderson, Tara C Gangadhar.

Abstract

Entities: Chemical Disease Species

Year: 2018 PMID： 30510087 DOI： 10.1158/1078-0432.CCR-18-3340

Source DB: PubMed Journal: Clin Cancer Res ISSN： 1078-0432 Impact factor: 12.531

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

1. Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.

Authors: Elizabeth J Davis; Matthew C Perez; Noura Ayoubi; Shilin Zhao; Fei Ye; Daniel Y Wang; Jeffrey A Sosman; Rami N Al-Rohil; Zeynep Eroglu; Douglas B Johnson
Journal: J Immunother Date: 2019 Jul/Aug Impact factor: 4.456

2. MS-HRM protocol: a simple and low-cost approach for technical validation of next-generation methylation sequencing data.

Authors: Ali Javadmanesh; Afsaneh Mojtabanezhad Shariatpanahi; Ehsan Shams Davodly; Marjan Azghandi; Maryam Yassi; Mehdi Heidari; Matin Kerachian; Mohammad Amin Kerachian
Journal: Mol Genet Genomics Date: 2022-05-26 Impact factor: 3.291

3. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.

Authors: Diwakar Davar; Hong Wang; Joe-Marc Chauvin; Ornella Pagliano; Julien J Fourcade; Mignane Ka; Carmine Menna; Amy Rose; Cindy Sander; Amir A Borhani; Arivarasan Karunamurthy; Ahmad A Tarhini; Hussein A Tawbi; Qing Zhao; Blanca H Moreno; Scott Ebbinghaus; Nageatte Ibrahim; John M Kirkwood; Hassane M Zarour
Journal: J Clin Oncol Date: 2018-10-25 Impact factor: 44.544

Review 4. PD-1/PD-L1 pathway: current researches in cancer.

Authors: Yanyan Han; Dandan Liu; Lianhong Li
Journal: Am J Cancer Res Date: 2020-03-01 Impact factor: 6.166

5. Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study.

Authors: David Chardin; Marie Paquet; Renaud Schiappa; Jacques Darcourt; Caroline Bailleux; Michel Poudenx; Aurélie Sciazza; Marius Ilie; Jonathan Benzaquen; Nicolas Martin; Josiane Otto; Olivier Humbert
Journal: J Immunother Cancer Date: 2020-07 Impact factor: 13.751

6. Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial.

Authors: Arwa Ali; Monica Dumbrava; Kylie Riddell; Nina Stewart; Robyn Ward; Ahmed K Ibrahim; Melvin Chin
Journal: BMC Cancer Date: 2020-04-22 Impact factor: 4.430

7. Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma.

Authors: Alison M Weppler; Andrew Pattison; Richard W Tothill; Shahneen Sandhu; Prachi Bhave; Paolo De Ieso; Jeanette Raleigh; Athena Hatzimihalis; Anthony J Gill; Shiva Balachander; Jason Callahan; Margaret Chua; George Au-Yeung; Grant A McArthur; Rodney J Hicks
Journal: J Immunother Cancer Date: 2020-10 Impact factor: 13.751